Rozemarijn S. Van Rijn

Leeuwarden, FR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.

IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.

Journal: Blood advances

Published: October 06, 2025

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal: Journal of the National Cancer Institute

Published: September 08, 2025

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Journal: Cell reports. Medicine

Published: June 30, 2025

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.

Journal: European journal of haematology

Published: April 23, 2025

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2024

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Journal: British journal of cancer

Published: October 04, 2024

Long-Term Survival in Patients With Advanced Melanoma.

Long-Term Survival in Patients With Advanced Melanoma.

Journal: JAMA network open

Published: August 14, 2024

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Journal: Cancers

Published: June 28, 2024

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine

Published: June 03, 2024

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Journal: Haematologica

Published: February 11, 2024

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

Journal: International journal of cancer

Published: December 01, 2023

Showing 1-12 of 65

Last Updated: 09/26/2026